FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245328049> ?p ?o ?g. }

• W4245328049 endingPage "15" @default.
• W4245328049 startingPage "5" @default.
• W4245328049 abstract "Objective: Our goal was to provide health-care providers, patients, and the general public with an assessment of currently available data regarding the use of adjuvant therapy for breast cancer. Participants: The participants included a non-Federal, non-advocate, 14-member panel representing the fields of oncology, radiology, surgery, pathology, statistics, public health, and health policy as well as patient representatives. In addition, 30 experts in medical oncology, radiation oncology, biostatistics, epidemiology, surgical oncology, and clinical trials presented data to the panel and to a conference audience of 1000. Evidence: The literature was searched with the use of MEDLINE® for January 1995 through July 2000, and an extensive bibliography of 2230 references was provided to the panel. Experts prepared abstracts for their conference presentations with relevant citations from the literature. Evidence from randomized clinical trials and evidence from prospective studies were given precedence over clinical anecdotal experience. Consensus Process: The panel, answering predefined questions, developed its conclusions based on the evidence presented in open forum and the scientific literature. The panel composed a draft statement, which was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately after its release at the conference and was updated with the panel's final revisions. The statement is available at http://consensus.nih.gov. Conclusions: The panel concludes that decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy should be offered only to women whose tumors express hormone receptor protein. Because adjuvant polychemotherapy improves survival, it should be recommended to the majority of women with localized breast cancer regardless of lymph node, menopausal, or hormone receptor status. The inclusion of anthracyclines in adjuvant chemotherapy regimens produces a small but statistically significant improvement in survival over non-anthracycline-containing regimens. Available data are currently inconclusive regarding the use of taxanes in adjuvant treatment of lymph node-positive breast cancer. The use of adjuvant dose-intensive chemotherapy regimens in high-risk breast cancer and of taxanes in lymph node-negative breast cancer should be restricted to randomized trials. Ongoing studies evaluating these treatment strategies should be supported to determine if such strategies have a role in adjuvant treatment. Studies to date have included few patients older than 70 years. There is a critical need for trials to evaluate the role of adjuvant chemotherapy in these women. There is evidence that women with a high risk of locoregional tumor recurrence after mastectomy benefit from postoperative radiotherapy. This high-risk group includes women with four or more positive lymph nodes or an advanced primary cancer. Currently, the role of postmastectomy radiotherapy for patients with one to three positive lymph nodes remains uncertain and should be tested in a randomized controlled trial. Individual patients differ in the importance they place on the risks and benefits of adjuvant treatments. Quality of life needs to be evaluated in selected randomized clinical trials to examine the impact of the major acute and long-term side effects of adjuvant treatments, particularly premature menopause, weight gain, mild memory loss, and fatigue. Methods to support shared decision-making between patients and their physicians have been successful in trials; they need to be tailored for diverse populations and should be tested for broader dissemination." @default.
• W4245328049 created "2022-05-12" @default.
• W4245328049 date "2001-12-01" @default.
• W4245328049 modified "2023-10-16" @default.
• W4245328049 title "National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000" @default.
• W4245328049 cites W1262485082 @default.
• W4245328049 cites W1562190372 @default.
• W4245328049 cites W1759175391 @default.
• W4245328049 cites W1847137107 @default.
• W4245328049 cites W1848579801 @default.
• W4245328049 cites W1876276942 @default.
• W4245328049 cites W1927722732 @default.
• W4245328049 cites W1938529209 @default.
• W4245328049 cites W1947335951 @default.
• W4245328049 cites W1955291661 @default.
• W4245328049 cites W1955397179 @default.
• W4245328049 cites W1955989670 @default.
• W4245328049 cites W1962532604 @default.
• W4245328049 cites W1974208182 @default.
• W4245328049 cites W1975829266 @default.
• W4245328049 cites W1976052438 @default.
• W4245328049 cites W1978173438 @default.
• W4245328049 cites W1994159961 @default.
• W4245328049 cites W2011251887 @default.
• W4245328049 cites W2014268944 @default.
• W4245328049 cites W2020321814 @default.
• W4245328049 cites W2032281192 @default.
• W4245328049 cites W2036934183 @default.
• W4245328049 cites W2052421758 @default.
• W4245328049 cites W2054028560 @default.
• W4245328049 cites W2059222393 @default.
• W4245328049 cites W2080886948 @default.
• W4245328049 cites W2085332509 @default.
• W4245328049 cites W2087419523 @default.
• W4245328049 cites W2092456443 @default.
• W4245328049 cites W2092931112 @default.
• W4245328049 cites W2097255042 @default.
• W4245328049 cites W2098529121 @default.
• W4245328049 cites W2099070927 @default.
• W4245328049 cites W2106431827 @default.
• W4245328049 cites W2112796338 @default.
• W4245328049 cites W2115293064 @default.
• W4245328049 cites W2121168781 @default.
• W4245328049 cites W2123927174 @default.
• W4245328049 cites W2128936801 @default.
• W4245328049 cites W2130840692 @default.
• W4245328049 cites W2131374394 @default.
• W4245328049 cites W2133764807 @default.
• W4245328049 cites W2139510434 @default.
• W4245328049 cites W2141647078 @default.
• W4245328049 cites W2147026385 @default.
• W4245328049 cites W2148078311 @default.
• W4245328049 cites W2153247110 @default.
• W4245328049 cites W2155216176 @default.
• W4245328049 cites W2156003808 @default.
• W4245328049 cites W2163456861 @default.
• W4245328049 cites W2164789874 @default.
• W4245328049 cites W2166631738 @default.
• W4245328049 cites W2167779518 @default.
• W4245328049 cites W2168517539 @default.
• W4245328049 cites W2214029008 @default.
• W4245328049 cites W2268646645 @default.
• W4245328049 cites W2326819825 @default.
• W4245328049 cites W2328710175 @default.
• W4245328049 cites W2343407300 @default.
• W4245328049 cites W2800860148 @default.
• W4245328049 cites W3128877721 @default.
• W4245328049 cites W4234660912 @default.
• W4245328049 cites W4237434210 @default.
• W4245328049 cites W4243828894 @default.
• W4245328049 cites W4252707264 @default.
• W4245328049 cites W4293107555 @default.
• W4245328049 cites W4320581625 @default.
• W4245328049 cites W4362046093 @default.
• W4245328049 doi "https://doi.org/10.1093/oxfordjournals.jncimonographs.a003460" @default.
• W4245328049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11773285" @default.
• W4245328049 hasPublicationYear "2001" @default.
• W4245328049 type Work @default.
• W4245328049 citedByCount "116" @default.
• W4245328049 countsByYear W42453280492012 @default.
• W4245328049 countsByYear W42453280492014 @default.
• W4245328049 countsByYear W42453280492015 @default.
• W4245328049 countsByYear W42453280492016 @default.
• W4245328049 countsByYear W42453280492017 @default.
• W4245328049 countsByYear W42453280492018 @default.
• W4245328049 countsByYear W42453280492019 @default.
• W4245328049 countsByYear W42453280492020 @default.
• W4245328049 countsByYear W42453280492021 @default.
• W4245328049 countsByYear W42453280492022 @default.
• W4245328049 crossrefType "journal-article" @default.
• W4245328049 hasBestOaLocation W42453280491 @default.
• W4245328049 hasConcept C112698675 @default.
• W4245328049 hasConcept C121608353 @default.
• W4245328049 hasConcept C126322002 @default.
• W4245328049 hasConcept C142724271 @default.
• W4245328049 hasConcept C144133560 @default.
• W4245328049 hasConcept C168563851 @default.
• W4245328049 hasConcept C17744445 @default.

• next